Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,876.00
Bid: 6,876.00
Ask: 6,878.00
Change: -104.00 (-1.49%)
Spread: 2.00 (0.03%)
Open: 6,950.00
High: 7,000.00
Low: 6,874.00
Yest. Close: 6,980.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Sanofi may win U.S. approval of $3 bln eczema drug by March

Sept 26 (Reuters) - French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March. Sanofi badly needs new products to make up for flag

26 Sep 16 07:24

AstraZeneca pulls cancer drug application in Europe

LONDON, Sept 21 (Reuters) - AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised by regulators reviewing the product. However, the Britis

21 Sep 16 10:21

Monday broker round-up

(ShareCast News) - Lloyds: Jefferies reiterates buy with a target price of 67p. Astrazeneca: UBS reiterates buy, 5480p target. Britvic: JP Morgan keeps at underweight with a 590p target. Unilever: UBS reiterates neutral with a 3380p target. IHG: HSBC starts coverage at reduce with a 2900p target.

19 Sep 16 09:52

Britain's FTSE falls as banking stocks lose ground

(ADVISORY - Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 ends down 0.3 pct at 6,710.28 points * Hefty Deutsche Bank demand hits banks * FTSE 100 still up around 8 pct so far

16 Sep 16 16:35

Astrazeneca says Forxiga combination beats use of drug alone

FRANKFURT, Sept 16 (Reuters) - AstraZeneca said combining its Forxiga type-2 diabetes drug with older medicine Bydureon was more effective at controlling blood sugar levels than treatment with either drug on its own. In a late stage trial, Forxiga and Bydureon were tested on patients whose

16 Sep 16 11:52

UPDATE 2-Aspen Pharmacare moves into China as South Africa sales dip

(Recasts with growth outside home market; adds CEO comment; adds smaller rival) JOHANNESBURG, Sept 14 (Reuters) - South Africa's Aspen Pharmacare Holdings will use its recent acquisitions of GlaxoSmithKline and AstraZeneca product lines to move into China, the firm's chief executive said.</

14 Sep 16 16:04

Broker tips: Pets at Home, Wood Group, Astrazeneca

(ShareCast News) - Citigroup initiated coverage of Pets at Home at 'buy' with a 275p price target, given its expectation of the medium-term margin upside opportunity and cash returns. The bank reckons that over the next 10 years, the vet business could generate an incremental £40m earnings before in

12 Sep 16 11:03

BUZZ-AstraZeneca: top FTSE 100 gainer on lung cancer drug hopes

** AstraZeneca top FTSE 100 gainer, up 0.6% in sharply lower market, after Jefferies calls out multibillion-dollar potential of durvalumab plus tremelimumab combination immunotherapy in lung cancer ** Price target upgraded to £58 a share from £54 ** Broker (4 stars for recommendatio

12 Sep 16 10:59

BUZZ-AstraZeneca: top FTSE 100 gainer on lung cancer drug hopes

** AstraZeneca top FTSE 100 gainer, up 0.6% in sharply lower market, after Jefferies calls out multibillion-dollar potential of durvalumab plus tremelimumab combination immunotherapy in lung cancer ** Price target upgraded to £58 a share from £54 ** Broker (4 stars for recommendatio

12 Sep 16 10:58

Monday broker round-up

(ShareCast News) - Autotrader: Barclays reiterates equal-weight with a target price of 375p. Hikma: Jefferies maintains buy with a 2500p target. Wood Group: Exane BNP Paribas upgrades to buy with a 815p target. Man Group: Citigroup upgrades to buy with a 137p target. McCarthy & Stone: Goldman Sac

12 Sep 16 09:24

Jefferies upgrades AstraZeneca to 'buy'

(ShareCast News) - Jefferies upgraded AstraZeneca to 'buy' from 'hold' and lifted the price target to 5,800p from 5,400p saying it sees a much higher probability of success and larger market opportunity from the MYSTIC study than consensus implies. The MYSTIC study is a global, phase 3 study of the

12 Sep 16 07:34

AstraZeneca Starts Two Trials On Type-2 Diabetes Drug

12 Sep 16 06:17

Consort Medical signs agreement with AstraZeneca

(ShareCast News) - Consort medical, a provider of advanced technology for drugs, has signed a new contract with pharmaceutical giant AstraZeneca for the supply of its Bespak respiratory devices. AstraZeneca and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Be

7 Sep 16 08:43

Consort Medical Sees Little Brexit Impact; Signs Deal With AstraZeneca

7 Sep 16 07:03

GSK's triple drug cuts flare-ups in chronic lung disease

By Ben Hirschler LONDON, Sept 6 (Reuters) - An experimental three-in-one inhaled drug from GlaxoSmithKline significantly cut flare-ups in patients with chronic lung disease in a clinical trial, researchers said on Tuesday. GSK is ahead of rivals AstraZeneca and Novartis in developing

6 Sep 16 13:45

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.